Earnings Call · Q2 FY2023·2023-08-08

Q2 23EPS -27.27%·Rev n/aQ1 23EPS +20.00%·Rev n/aQ4 22EPS +37.50%·Rev n/aQ3 22EPS -6.67%·Rev n/a⚠ consensus missing

Xeris Biopharma Holdings, Inc. XERS

Allison Wey — Unknown (likely IR or Communications based on context)

Paul Edick — Chairman and CEO

Steven Pieper — CFO or similar financial executive

+3.6%1d on move date+4.0% vs SPY3d−6.4%5d−9.6%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more XERS calls or request research access.

More XERS calls Browse calls Request research access